Alkermes plc
NASDAQ:ALKS · NASDAQ Global Select
+$0.79 today
Vol 7.73M · Avg 2.33M
Filings
Ground the analysis in primary documents
Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.
Price History
Dividend-adjusted closing price
Change
+53.76%
Period High
$44.99
Period Low
$26.13
Latest
$44.99
SEC Filings
Recent regulatory filings
No filings found.
Competitors
Peer companies in the same sector
Arrowhead Pharmaceuticals, Inc.
NASDAQ:ARWR
$11.71B
TG Therapeutics, Inc.
NASDAQ:TGTX
$8.01B
Vaxcyte, Inc.
NASDAQ:PCVX
$7.59B
Kymera Therapeutics, Inc.
NASDAQ:KYMR
$7.52B
Protagonist Therapeutics, Inc.
NASDAQ:PTGX
$7.27B
Arcellx, Inc.
ACLX
$6.73B
PTC Therapeutics, Inc.
NASDAQ:PTCT
$6.54B
CRISPR Therapeutics AG
NASDAQ:CRSP
$5.29B
Akero Therapeutics, Inc.
AKRO
$4.50B
ACADIA Pharmaceuticals Inc.
NASDAQ:ACAD
$3.70B
What is the latest ALKS filing?
The latest filing shown is 8-K dated Jun 15, 2026.
How many recent filings does ALKS have?
Intrinsic Alpha currently shows 20 recent filings for ALKS.
Explore More
Continue the stock analysis
Jump to another research area for this company.